Dupixent Approved for Atopic Dermatitis in Younger Pediatric Patients
The Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of moderate to severe atopic dermatitis in pediatric patients aged 6 months to 5 years whose disease is not adequately controlled with…